| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29K | — | +27.3% |
| Cost of Revenue | $1K | — | -34.1% |
| R&D Expense | $3.5M | — | +13.0% |
| SG&A Expense | $3.3M | — | +77.6% |
| Operating Income | -$6.7M | — | -37.1% |
| Income Tax | $0 | — | — |
| Net Income | -$6.3M | — | -34.1% |
| EPS (Basic) | -$0.04 | — | +0.0% |
| EPS (Diluted) | -$0.04 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $75.1M | +8.8% | +199.9% |
| Accounts Receivable | $216K | +13.1% | +1050.7% |
| Current Assets | $76.5M | +9.6% | +199.4% |
| Total Assets | $85.9M | +8.5% | +141.1% |
| Current Liabilities | $2.3M | +5.4% | +46.4% |
| Total Liabilities | $4.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.1M | — | -16.4% |
| Capital Expenditures | $450K | — | -47.2% |
| Investing Cash Flow | -$621K | — | +30.9% |
| Financing Cash Flow | $10.8M | — | +509.4% |
| Free Cash Flow | -$4.5M | — | -3.9% |
| +12.5% |
| Stockholders' Equity | $81.3M | +8.9% | +157.7% |